Poxel Announces Participation in Upcoming Virtual Investor Conferences
28 Mai 2020 - 5:45PM
Business Wire
POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical
company focused on the development of innovative treatments for
metabolic disorders, including type 2 diabetes and non-alcoholic
steatohepatitis (NASH), today announced that members of the Poxel
management team will participate in several upcoming virtual
investor conferences held in June 2020.
Jefferies Virtual Healthcare Conference 2020 Date: June
2-4, 2020 Thomas Kuhn, CEO, will present a corporate overview on
Wednesday, June 3, 2020 from 9:30 to 9:55 am EDT. Members of the
Poxel management team will be available for one-on-one virtual
meetings.
To access the webcast, please visit:
http://wsw.com/webcast/jeff126/poxel.pa/. The webcast replay will
remain available for 90 days following the live presentation.
Citi European Virtual Healthcare Conference 2020 Date:
June 16-17, 2020 Members of the Poxel management team will be
available for one-on-one virtual meetings.
Forum MIDCAPS Gilbert Dupont Date: June 18, 2020 Members
of the Poxel management team will be available for one-on-one
virtual meetings.
About Poxel SA
Poxel is a dynamic biopharmaceutical company that uses
its extensive expertise in developing innovative drugs for
metabolic diseases, with a focus on type 2 diabetes and
non-alcoholic steatohepatitis (NASH). In its mid-to-late
stage pipeline, the Company is currently advancing three drug
candidates as well as earlier-stage opportunities.
Imeglimin, Poxel’s first-in-class lead product, targets
mitochondrial dysfunction. Together, with its partner Sumitomo
Dainippon Pharma, Poxel successfully completed the Phase 3
Trials of IMeglimin for Efficacy and
Safety (TIMES) program for the treatment of type 2 diabetes
in Japan. Poxel also established a partnership with Roivant
Sciences for Imeglimin’s development and commercialization in
countries outside of the partnership with Sumitomo Dainippon
Pharma, including the U.S. and Europe. PXL770, a
first-in-class direct adenosine monophosphate-activated protein
kinase (AMPK) activator, is in a Phase 2a proof-of-concept program
for the treatment of NASH. PXL770 could also have the potential to
treat additional metabolic diseases. PXL065
(deuterium-stabilized R-pioglitazone), a mitochondrial pyruvate
carrier (MPC) inhibitor, is advancing into a Phase 2 clinical trial
for the treatment of NASH. Poxel also has additional earlier-stage
programs targeting metabolic, specialty and rare diseases. The
Company intends to generate further growth through strategic
partnerships and pipeline development. Listed on Euronext Paris,
Poxel is headquartered in Lyon, France, and has subsidiaries in
Boston, MA, and Tokyo, Japan. For more information, please visit:
www.poxelpharma.com.
In the context of the COVID-19 outbreak, which was declared a
pandemic by the World Health Organization (WHO) on March 12, 2020,
the Company has undertaken a full review of the impact of the
outbreak on its business. Considering the rapidly evolving
situation, the Company is updating this assessment on a regular
basis.
The Company anticipates that the COVID-19 pandemic could have a
material negative impact on its business operations. The worldwide
impact of COVID-19 may notably affect the Company’s internal
organization and efficiency, particularly in countries where it
operates and where confinement measures have been implemented by
the authorities. In addition, the deteriorating market conditions
may impact the Company’s ability to raise additional funding and/or
to enter into partnerships. Particularly, delays in the supply of
drug substance or drug products, in pre-clinical and/or clinical
trials, as well as delays linked to the responsiveness of
regulatory authorities could occur, which could potentially have an
impact on the Company’s development programs. The Company will
continue to proactively monitor the situation.
All statements other than statements of historical fact included
in this press release about future events are subject to (i) change
without notice and (ii) factors beyond the Company’s control. These
statements may include, without limitation, any statements preceded
by, followed by or including words such as “target,” “believe,”
“expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,”
“project,” “will,” “can have,” “likely,” “should,” “would,” “could”
and other words and terms of similar meaning or the negative
thereof. Forward-looking statements are subject to inherent risks
and uncertainties beyond the Company’s control that could cause the
Company’s actual results or performance to be materially different
from the expected results or performance expressed or implied by
such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200528005488/en/
Poxel SA Jonae R. Barnes Senior Vice President, Investor
Relations, Corporate Communications and Public Relations
jonae.barnes@poxelpharma.com +1 617 818 2985
Aurélie Bozza Investor Relations & Communication Director
aurelie.bozza@poxelpharma.com +33 6 99 81 08 36
Investor relations / Media - EU/US Trophic Communications
Joanne Tudorica or Valeria Fisher tudorica@trophic.eu or
fisher@trophic.eu +49 171 351 2733 or +49 175 804 1816
Investor relations / Media - France NewCap Emmanuel Huynh
or Arthur Rouillé poxel@newcap.eu +33 1 44 71 94 94
Poxel (EU:POXEL)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Poxel (EU:POXEL)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024